Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Biohaven bounces back with phase 3 ultra-rare disease win
Biohaven linked troriluzole to a slowing of progression, setting it up to take another shot at approval with an asset that the FDA refused to review.
Nick Paul Taylor
Sep 23, 2024 9:22am
FDA scraps adcomm for Applied's rare disease drug
Sep 18, 2024 8:00am
More collaborative FDA can accelerate rare disease R&D: report
Sep 13, 2024 5:00am
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 7:00am
Novartis ignites new stage of Voyager pact with $15M capsid deal
Sep 5, 2024 9:45am
Cyclo Therapeutics merges with longtime backer Rafael Holdings
Aug 22, 2024 8:50am